Meinig J Matthew, Nelson Michelle, Cote Christopher K, Emmett Stevan R, Harding Sarah V
Bacteriology Division, United States Army Medical Research Institute of Infectious Diseases, Frederick, MD, United States.
Defence Science and Technology Laboratory, Porton Down, Salisbury, United Kingdom.
Front Antibiot. 2025 Aug 14;4:1611588. doi: 10.3389/frabi.2025.1611588. eCollection 2025.
The development of medical countermeasures against pathogens of biodefense concern remains critical to protecting military and public health. This review compares data detailing antibacterial activity and efficacy for a selection of antibiotics evaluated against potential bacterial biothreat pathogens. The human safety and tolerability of these formulations were also considered. This review includes finafloxacin, levofloxacin, delafloxacin, omadacycline, gepotidacin, tebipenem and sulopenem. The selection criteria of these antibiotics were 1) the availability of an oral formulation, 2) the regulatory status (licensed by a regulatory authority or in an advanced stage of development) and 3) the availability of publicly available information on the biodefence pathogens of concern. We hope to highlight approved or advanced clinical candidates that have significant and unique potential in the biodefense space which may be deployed to protect both the public and warfighter against these bacterial infections.
研发针对具有生物防御意义的病原体的医学应对措施对于保护军事和公众健康仍然至关重要。本综述比较了针对一系列潜在细菌生物威胁病原体评估的多种抗生素的抗菌活性和疗效的详细数据。还考虑了这些制剂的人体安全性和耐受性。本综述包括非那沙星、左氧氟沙星、德拉沙星、奥马环素、吉波沙星、替比培南和舒洛培南。这些抗生素的选择标准为：1）有口服制剂；2）监管状态（已获监管机构批准或处于研发后期）；3）有关于相关生物防御病原体的公开可用信息。我们希望重点介绍在生物防御领域具有重大且独特潜力的已批准或处于临床后期的候选药物，这些药物可用于保护公众和作战人员免受这些细菌感染。
